{"prompt": "['Alliance A221701', 'Table of Contents', '1.0', 'Background', '9', '1.1', 'Introduction', '9', '1.2', 'Larger phase II trials of corticosteroids for prevention of everolimus-associated stomatitis', '9', '1.3', 'Rationale for a randomized phase III trial', '10', '1.4', 'Study design', '10', '1.5', 'Potential study populations', '11', '1.6', 'Methods and Assessment Procedures', '11', '2.0', 'Objectives', '13', '2.1', 'Co-Primary objectives', '13', '2.2', 'Secondary objectives', '13', '2.3', 'Pharmacogenetics objectives (also see Section 14.1.2)', '13', '2.4', 'Pharmacokinetics objectives (also see Section 14.2.2)', '13', '3.0', 'Patient Selection', '14', '3.1', 'On-Study Guidelines', '14', '3.2', 'Eligibility Criteria', '14', '4.0', 'Patient Registration', '16', '4.1', 'Investigator and Research Associate Registration with CTEP', '16', '4.2', 'CTSU Site Registration Procedures.', '17', '4.3', 'Patient Registration Requirements', '19', '4.4', 'Patient Enrollment (registration/randomization procedures (Step 1))', '19', '4.5', 'Registration to Correlative and Companion Studies', '20', '4.6', 'Stratification Factors and Treatment Assignments', '20', '4.7', 'Procedures for Double-Blinding the Treatment Assignment', '21', '5.0', 'Study Calendar', '22', '6.0', 'Data and Specimen Submission', '23', '6.1', 'Data Collection and Submission', '23', '6.2', 'Specimen collection and submission', '25', '7.0', 'Treatment Plan/Intervention', '28', '7.1', 'Everolimus.', '28', '7.2', 'Initial Dexamethasone/Placebo', '28', '7.3', 'Open label dexamethasone', '28', '8.0', 'Dose and Treatment Modifications, Unblinding', '29', '6', 'NCI version date 8/14/2020', 'Update #03']['Alliance A221701', '8.1', 'Ancillary Therapy, Concomitant Medications, and Supportive Care', '29', '8.2', 'Dose Modifications', '29', '8.3', 'Unblinding Procedures.', '29', '9.0', 'Adverse Events', '31', '9.1', 'Routine Adverse Event Reporting', '31', '9.2', 'CTCAE Routine Reporting Requirements', '32', '9.3', 'Expedited Adverse Event Reporting (CTEP-AERS)', '32', '10.0', 'Drug Information', '36', '10.1', 'Dexamethasone Oral Solution', '36', '10.2', 'Placebo Oral Solution', '38', '11.0 Measures', '39', '11.1', 'Numerical Analogue Mouth Pain Scale (Appendix II)', '39', '11.2', 'Numerical Analogue Self-Assessment (Appendix III)', '39', '11.3', 'PRO-CTCAE items (Mouth/throat sores, Sleep and Fatigue items) (Appendix IV)', '39', '11.4', 'Patient reported Mouthwash Use frequency (Appendix V)', '39', '11.5', 'Nurse\\\\Research coordinator weekly phone call assessments (Appendix VI)', '39', '11.6', 'Normalcy of Diet Scale (Appendix VII)', '40', '12.0', 'End of Treatment/Intervention', '40', '12.1', 'Duration of Protocol Treatment', '40', '12.2', 'Criteria for Discontinuation of Protocol Treatment/Intervention', '40', '12.3', 'Follow-up', '41', '12.4', 'Extraordinary Medical Circumstances', '41', '12.5', 'Managing ineligible patients and registered patients who never receive protocol intervention 41', '13.0', 'Statistical Considerations', '42', '13.1', 'Study Design', '42', '13.2', 'Sample Size, Accrual time and Study Duration', '42', '13.3', 'Primary objectives and endpoints', '42', '13.4', 'Secondary objectives and endpoints', '42', '13.5', 'Analysis Plan and Sample Size Justification', '43', '13.6', 'Interim data analysis and stopping rule', '45', '13.7', 'Primary Endpoint Justification: CTCAE items', '45', '13.8', 'Sample Size and Power Considerations', '46', '13.9', 'Study Monitoring', '48', '13.10', 'Missing Data and sensitivity analysis', '48', '13.11', 'Inclusion of Women and Minorities.', '50', '14.0', 'Correlative And Companion Studies', '51', '7', 'NCI version date 8/14/2020', 'Update #03']\n\n###\n\n", "completion": "END"}